Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Perfusion ; 31(2): 169-71, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25987552

RESUMO

Massive pulmonary embolism is a leading cause of death during pregnancy. While the prevention of thromboembolic disease during the peripartum period is codified, there is no consensus regarding its treatment. We report two cases of pregnant women who had massive pulmonary embolisms (PE) and shock treated with veno-arterial extracorporeal life support (ECLS) and heparin therapy.Haemodynamic and oxygenation parameters were rapidly restored. The patients completely recovered and the pregnancies continued. The patients did not develop pulmonary hypertension. ECLS can be considered as a successful treatment option of massive pulmonary embolism during pregnancy.


Assuntos
Heparina/administração & dosagem , Sistemas de Manutenção da Vida , Complicações Cardiovasculares na Gravidez , Embolia Pulmonar , Adulto , Feminino , Hemodinâmica/efeitos dos fármacos , Humanos , Gravidez , Complicações Cardiovasculares na Gravidez/sangue , Complicações Cardiovasculares na Gravidez/fisiopatologia , Complicações Cardiovasculares na Gravidez/terapia , Embolia Pulmonar/sangue , Embolia Pulmonar/fisiopatologia , Embolia Pulmonar/terapia
2.
J Card Surg ; 21(1): 17-21, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16426342

RESUMO

BACKGROUND AND AIM OF THE STUDY: Off-pump coronary artery bypass (OPCAB) enables a reduction in postoperative complications, particularly bleeding and transfusion. Nevertheless, a significant percentage of patients still needs transfusion. The effect of antifibrinolytic therapy on postoperative bleeding as part of OPCAB is still not widely described. The purpose of this study was to investigate the potential benefit of aprotinin in OPCAB. METHODS: We conducted a retrospective comparative study with a historical control group. Consecutive patients undergoing off-pump coronary bypass were divided in two groups: 40 patients were operated without any antifibinolytic drug (group C); 40 patients received aprotinin (group A) during surgery. Patients in group A received a bolus of 2 x 10(6) KIU during 30 minutes, followed by a continuous infusion of 0.5 x 10(6) KIU per hour until the end of surgery. The same protocol was used during the whole study period. RESULTS: Preoperative data of the two groups did not differ except for the number of grafts performed, which was higher in group A. Prothrombin time and activated clotting time increased in both groups after surgery. The use of packed red blood cells or fresh frozen plasma was not significantly different between both groups. Postoperative blood loss was significantly reduced in the aprotinin group (540 mL +/- 320 vs. 770 mL +/- 390, p = 0.006). No increase in postoperative troponin values was found in group A. CONCLUSIONS: Aprotinin significantly reduced postoperative blood loss without reducing the transfusion rate. Aprotinin was not associated with any increase in postoperative complications.


Assuntos
Aprotinina/uso terapêutico , Ponte de Artéria Coronária sem Circulação Extracorpórea/efeitos adversos , Estenose Coronária/cirurgia , Hemostáticos/uso terapêutico , Hemorragia Pós-Operatória/prevenção & controle , Idoso , Aprotinina/administração & dosagem , Estenose Coronária/sangue , Seguimentos , Hemostáticos/administração & dosagem , Humanos , Infusões Intravenosas , Hemorragia Pós-Operatória/sangue , Hemorragia Pós-Operatória/etiologia , Tempo de Protrombina , Estudos Retrospectivos , Resultado do Tratamento , Tempo de Coagulação do Sangue Total
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA